108 related articles for article (PubMed ID: 29749548)
21. miR‑146b‑5p suppresses glioblastoma cell resistance to temozolomide through targeting TRAF6.
Qian Z; Zhou S; Zhou Z; Yang X; Que S; Lan J; Qiu Y; Lin Y
Oncol Rep; 2017 Nov; 38(5):2941-2950. PubMed ID: 29048680
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
23. Combination therapy with micellarized cyclopamine and temozolomide attenuate glioblastoma growth through Gli1 down-regulation.
Liu YJ; Ma YC; Zhang WJ; Yang ZZ; Liang DS; Wu ZF; Qi XR
Oncotarget; 2017 Jun; 8(26):42495-42509. PubMed ID: 28477008
[TBL] [Abstract][Full Text] [Related]
24. Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma.
Sun Q; Pei C; Li Q; Dong T; Dong Y; Xing W; Zhou P; Gong Y; Zhen Z; Gao Y; Xiao Y; Su J; Ren H
Biochem Biophys Res Commun; 2018 Feb; 496(4):1040-1046. PubMed ID: 29366782
[TBL] [Abstract][Full Text] [Related]
25. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
26. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.
Ciammella P; Galeandro M; D'Abbiero N; Podgornii A; Pisanello A; Botti A; Cagni E; Iori M; Iotti C
Clin Neurol Neurosurg; 2013 Sep; 115(9):1609-14. PubMed ID: 23453151
[TBL] [Abstract][Full Text] [Related]
27. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
28. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
[TBL] [Abstract][Full Text] [Related]
29. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
Athanassiou H; Synodinou M; Maragoudakis E; Paraskevaidis M; Verigos C; Misailidou D; Antonadou D; Saris G; Beroukas K; Karageorgis P
J Clin Oncol; 2005 Apr; 23(10):2372-7. PubMed ID: 15800329
[TBL] [Abstract][Full Text] [Related]
30. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
Stupp R; Dietrich PY; Ostermann Kraljevic S; Pica A; Maillard I; Maeder P; Meuli R; Janzer R; Pizzolato G; Miralbell R; Porchet F; Regli L; de Tribolet N; Mirimanoff RO; Leyvraz S
J Clin Oncol; 2002 Mar; 20(5):1375-82. PubMed ID: 11870182
[TBL] [Abstract][Full Text] [Related]
31. Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy.
Golden EB; Cho HY; Jahanian A; Hofman FM; Louie SG; Schönthal AH; Chen TC
Neurosurg Focus; 2014 Dec; 37(6):E12. PubMed ID: 25434381
[TBL] [Abstract][Full Text] [Related]
32. Entry and exit of chemotherapeutically-promoted cellular dormancy in glioblastoma cells is differentially affected by the chemokines CXCL12, CXCL16, and CX3CL1.
Adamski V; Hattermann K; Kubelt C; Cohrs G; Lucius R; Synowitz M; Sebens S; Held-Feindt J
Oncogene; 2020 May; 39(22):4421-4435. PubMed ID: 32346064
[TBL] [Abstract][Full Text] [Related]
33. Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells.
Paul-Samojedny M; Pudełko A; Kowalczyk M; Fila-Daniłow A; Suchanek-Raif R; Borkowska P; Kowalski J
BioDrugs; 2016 Apr; 30(2):129-44. PubMed ID: 26902608
[TBL] [Abstract][Full Text] [Related]
34. Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide.
Badiyan SN; Markovina S; Simpson JR; Robinson CG; DeWees T; Tran DD; Linette G; Jalalizadeh R; Dacey R; Rich KM; Chicoine MR; Dowling JL; Leuthardt EC; Zipfel GJ; Kim AH; Huang J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):877-85. PubMed ID: 25257812
[TBL] [Abstract][Full Text] [Related]
35. The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.
Atif F; Patel NR; Yousuf S; Stein DG
PLoS One; 2015; 10(6):e0131441. PubMed ID: 26110872
[TBL] [Abstract][Full Text] [Related]
36. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
37. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
[TBL] [Abstract][Full Text] [Related]
38. Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity.
Zhang Z; Wang Y; Chen J; Tan Q; Xie C; Li C; Zhan W; Wang M
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1289-1296. PubMed ID: 27832326
[TBL] [Abstract][Full Text] [Related]
39. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
40. Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme.
Tuettenberg J; Grobholz R; Korn T; Wenz F; Erber R; Vajkoczy P
J Cancer Res Clin Oncol; 2005 Jan; 131(1):31-40. PubMed ID: 15565458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
